Colorectal cancer represents the second most common malignancy worldwide, with approximately one million newly diagnosed cases each year, and is the fourth leading cause of cancer mortality. This article provides an overview of the role of FDG (fluorodeoxyglucose) PET (positron emission tomography) CT (computed tomography) for assessment in patients with colorectal cancer.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.

Stay up to date with
RAD Magazine

Sign up for our newsletter.

We care about your data. Read our privacy policy.